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Abstract
Background: Clear cell renal carcinoma (RCC) is the most common and invasive adult renal cancer. For the purpose of
identifying RCC biomarkers, we investigated chromosomal regions and individual genes modulated in RCC pathology. We
applied the dual strategy of assessing and integrating genomic and transcriptomic data, today considered the most effective
approach for understanding genetic mechanisms of cancer and the most sensitive for identifying cancer-related genes.
Results: We performed the first integrated analysis of DNA and RNA profiles of RCC samples using Affymetrix technology.
Using 100K SNP mapping arrays, we assembled a genome-wide map of DNA copy number alterations and LOH areas. We thus
confirmed the typical genetic signature of RCC but also identified other amplified regions (e.g. on chr. 4, 11, 12), deleted regions
(chr. 1, 9, 22) and LOH areas (chr. 1, 2, 9, 13). Simultaneously, using HG-U133 Plus 2.0 arrays, we identified differentially
expressed genes (DEGs) in tumor vs. normal samples. Combining genomic and transcriptomic data, we identified 71 DEGs in
aberrant chromosomal regions and observed, in amplified regions, a predominance of up-regulated genes (27 of 37 DEGs) and
a trend to clustering. Functional annotation of these genes revealed some already implicated in RCC pathology and other
cancers, as well as others that may be novel tumor biomarkers.
Conclusion: By combining genomic and transcriptomic profiles from a collection of RCC samples, we identified specific
genomic regions with concordant alterations in DNA and RNA profiles and focused on regions with increased DNA copy
number. Since the transcriptional modulation of up-regulated genes in amplified regions may be attributed to the genomic
alterations characteristic of RCC, these genes may encode novel RCC biomarkers actively involved in tumor initiation and
progression and useful in clinical applications.
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Background
Clear cell (or conventional) renal cell carcinoma (RCC)
accounts for about 85% of all primary kidney malignan-
cies and, although familial forms of RCC exist, the disease
is more often sporadic[1]. This pathology is associated
with genetic alterations affecting particular chromosomes
[2,3]. The most frequent findings are deletions and unbal-
anced translocations involving chromosome 3p, resulting
in the loss of specific regions, e.g. 3p25-p26 including the
von Hippel-Lindau (VHL) gene locus [4]. Duplications of
chromosomes 5q and 7 and deletions on chromosomes
6q, 8p, 9p and 14q are other typical chromosomal abnor-
malities. Another recurrent RCC genetic feature is a partic-
ular pattern of loss of heterozygosity (LOH), i.e. the
change from a heterozygous genotype in a normal sample
to a homozygous one in a tumor, with a high frequency of
allelic imbalances on chromosome 3p in conjunction
with 6q, 8p, 9p and q, and 14q [5]. These DNA alterations
define a specific pattern of genetic instability, which rep-
resent a tumor-specific molecular fingerprint potentially
useful for diagnostic applications [3]. In addition, some of
these DNA alterations have been associated with tumor
progression and metastatic potential, and so may be use-
ful prognostic indicators [2]. Furthermore, many studies
have profiled transcriptional patterns in RCC samples, but
a univocally accepted gene expression signature is lacking
[6].
Until now, chromosomal imbalances (i.e. amplifications
and deletions) in neoplastic diseases have been studied
with a variety of methods, such as cytogenetic techniques,
comparative genomic hybridization (CGH) and the new-
est array-CGH, and fluorescence in situ hybridization
(FISH), but each suffers limitations in resolution or high-
throughput capacity [7,8]. The recent development of sin-
gle nucleotide polymorphism (SNP) array technology has
greatly improved the detection of DNA copy number
(CN) changes, and now allows the simultaneous genotyp-
ing of more than 100,000 polymorphic loci distributed
across all human chromosomes and thus the high-resolu-
tion scanning of the entire genome [9]. Moreover, by allel-
otyping the DNA sequence, this technology permits the
detection of LOH events, which has principally been per-
formed by investigating microsatellite markers at specific
genomic regions. The assessment of areas rich in LOH
events is a useful approach for identifying regions poten-
tially harboring novel tumor suppressor genes (TSGs)
[10]. Thus, SNP mapping technology permits the simulta-
neous analysis, at whole genome level and on the same
platform, of chromosomal and allelic imbalances. More-
over, it permits the distinction between LOH associated
with CN changes (such as hemizygous deletions) and that
associated with a CN neutral status, due to different mech-
anisms including mitotic recombination, gene conversion
and mitotic non-disjunction leading to uniparental dis-
omy (UPD). Simultaneous assessment of LOH and CN
changes at high resolution (more than 50,000 SNPs) has
been recently performed in prostate cancers [11] and glio-
mas [12], but not yet in RCC.
There is an increasing tendency to combine genomic anal-
ysis with transcriptomic profiles, in order to study the rela-
tion between CN changes and gene expression levels. The
integration of CGH profiles and transcriptional data has
demonstrated that CN alterations have a clear impact on
expression levels, in a variety of tumors [13-15]. Cur-
rently, this dual strategy is considered the most effective
approach for interpreting genome-wide data about DNA
and RNA anomalies in cancer, in order to identify chro-
mosomal regions and genes involved in tumor initiation
and progression. The proof of principle comes from the
study by Garraway et al. [16], in which the combined anal-
ysis of genome-wide SNP-based CN data and expression
profiles led to the identification of a candidate lineage-
specific oncogene associated with a novel amplification in
malignant melanoma. Concerning RCC, Furge et al. [17]
developed a computational approach to predict cytoge-
netic abnormalities from gene expression data and con-
firmed alterations on chromosomes 3 and 5 as the typical
DNA signature of this pathology. However, an integrated
analysis of DNA and RNA from RCC samples using
genome-wide approaches has not yet been reported.
In this study, we applied the 100K SNP mapping array
technology to assemble a detailed genome-wide map of
copy number alterations (CNAs) and LOH events in a col-
lection of 27 RCC tissue samples. Moreover, we combined
genomic data with the transcriptomic profile to identify
chromosomal regions and individual genes modulated by
the underlying DNA alterations and thus potentially use-
ful in clinical applications as novel RCC constitutive
markers.
Results
Visualization of the genomic profile of RCC samples
DNA copy number alterations (CNAs) were assessed at
the genomic level in a set of 27 RCC samples, using Gene-
Chip® 50K Hind array data and CNAG v2.0 software.
Regions of CN gain and loss occurring in each sample
along the entire genome are shown in a unique plot (Fig-
ure 1). All autosomes were affected by CN gain or loss, or
both. The most recurrent CN gains were on chromosomes
5, 7, 11, 12, 14, 15, 16, 19 and 20, while CN losses mostly
occurred on chr. 3p, 6q, 9q and 10q. Taken as a whole,
these results illustrate a great heterogeneity in CNA profile
among the 27 tumor samples.
To increase the resolution of our analysis, we combined
data from both GeneChip® 50K Xba and 50K Hind arrays
and performed a comprehensive analysis usingMolecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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dChip2006 software. For each chromosome, we assem-
bled a detailed map showing both CNAs and LOH regions
in each tumor sample (Additional file 1). By a visual
inspection, each sample presented a specific pattern of
CNAs, with different distributions and lengths, thus con-
firming the wide heterogeneity previously observed. Tak-
ing into account the whole sample set, the chromosomes
harboring the largest aberrant regions were 3, 4, 5, 6, 7, 9,
12 and 20, while regarding LOH events, chromosomes 3,
6 and 9 were the most commonly affected. By simultane-
ously mapping both CNAs and LOH regions along all
chromosomes, we observed that LOH events were usually
accompanied by CN loss or CN neutral status, except for
single small regions on chr. 2, 9, 11, 13, 14 and 16 show-
ing LOH and concomitant CN gain. Thus, this analysis
offers an immediate and comprehensive view of all CNAs
and LOH events in the 27 tumor samples, allowing a
more complete understanding of the complex genetic
rearrangements underlying RCC pathology.
Genome-wide assessment of LOH events in RCC samples
Using dChip2006 we identified chromosomal regions
affected by significant LOH over all tumor samples. Cal-
culating the probability across the whole sample set, we
obtained LOH scores ranging from 0.07 to 0.22 and a cor-
responding number of affected chromosomes progres-
sively decreasing from 15 to 1 (Table 1). Interestingly,
setting LOH threshold at the maximum value of 0.22,
only chromosome 3p was significantly affected by LOH,
highlighting the high frequency and importance of this
alteration in RCC pathology. To reach the best compro-
mise between stringency and background noise, we
selected regions with LOH score greater or equal to 0.15,
thus identifying six chromosomes significantly affected by
LOH over all samples, i.e. 1p, 2q, 3p, 3q, 6q, 9q and 13q.
To further investigate these significant LOH regions, we
calculated their exact position, length and frequency
(Table 2). We found 15 LOH regions distributed across
the six chromosomes, among which four were located on
chr. 3p and six were on chr. 6q. Chromosomes 1p, 2q, 9q
and 13q had only one significant LOH region each. These
regions spanned from 1 to 4 Mb, with frequencies ranging
from 3 (11%) to 11 samples (41%). Interestingly, the
most frequent LOH region was also one of the largest, cov-
ering 4 Mb on chr. 3p26.2-p25.3 and adjacent to other 4
Mb on chr. 3p24.3 and 1 Mb on chr. 3p14.3 showing
LOH events in 26% and 30% samples, respectively, thus
confirming the crucial involvement of chr. 3p in RCC eti-
ology. Moreover, chromosome 6q presented three large
LOH areas from 6q22.1 to 6q25.3, suggesting the pres-
ence of a wide region potentially involved in RCC pathol-
ogy. Considering the corresponding DNA copy number
status, these LOH regions were associated with either CN
loss or CN neutral status, while no CN gain events were
observed (Table 2). In particular, CN loss accompanied
LOH on chr. 1p and 9q, while diploid copy number was
retained on chr. 2q and 13q. Chromosomes 3 and 6
showed a more complex pattern, presenting LOH events
with both CN loss and neutral in different tumor samples.
Table 1: Chromosomes affected by significant LOH according to LOH score thresholds as calculated by dChip2006.
LOH
threshold
Chromosomes, n Affected chromosomal arms
0.07 15 1p, 1q, 2p, 2q, 3p, 3q, 5q, 6p, 6q, 8p, 8q, 9p, 9q, 10p, 10q, 12p, 12q, 13p,13q, 14q, 17p, 17q, 18p, 18q, 21q, 22q
0.11 11 1p, 1q, 2p, 2q, 3p, 3q, 6p, 6q, 8p, 8q, 9p, 9q, 10p, 10q, 12p, 13q, 17q, 21q
0.15 6 1p, 2q, 3p, 3q, 6q, 9q, 13q
0.19 2 3p, 6q
0.22 1 3p
Abbreviations: p, short arm; q, long arm.
DNA copy number alterations in the 27 RCC samples as  identified by CNAG v2.0 software Figure 1
DNA copy number alterations in the 27 RCC sam-
ples as identified by CNAG v2.0 software. All chromo-
somes are represented with cytobands (black and white 
blocks), centromere (green blocks) and heterochromatic 
regions (red and blue blocks). Each tumor sample was com-
pared to its matched normal blood sample, and regions of 
DNA copy number gain (red lines) and copy number loss 
(green lines) were plotted along each chromosome. Datasets 
from only GeneChip® 50K Hind arrays were used.Molecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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Specifically, on chr. 3p, all LOH areas had no CN change,
except for 3p26.2-p25.3, the most frequent and largest
LOH region, which presented both CN loss and CN neu-
tral status in 4 and 7 samples, respectively.
When we referred back to the individual samples, some
interesting patterns emerged. Noticeably, on chr. 6q, 9q
and 13q, we observed groups of samples showing similar
LOH patterns, i.e. samples no. 27CG, 46SA and 60CC for
LOH on chr. 6q, samples no. 33BV, 35PA, 36MMl on chr.
9q, and samples no. 36MMl, 46SA, and 60CC on chr. 13q
(Additional file 1). The fact that these cases presented bio-
logical features of potential aggressiveness (relatively
larger tumor diameter, and higher tumor stage and grade)
or clinical evidence of invasive capacity (cases no. 35PA
and 60CC had tumor recurrence) suggests that their simi-
lar LOH patterns on chr. 6q, 9q and 13q may be a specific
fingerprint of RCC malignant potential. Among the six
LOH regions on chr. 6q, four had diploid copy number in
most samples, while two (on chr. 6q22.31 and 6q25.2-
q25.3, respectively) were accompanied by CN loss in 3 of
4 cases. Interestingly, the three samples with CN loss were
no. 27CG, 46SA and 60CC, suggesting the presence of a
particular combined pattern of LOH and CN loss distin-
guishing these cases. Taken as a whole, these results
allowed the assembly of a detailed map of significant
LOH regions across the whole sample set and evidenced
the presence of different mechanisms, such as
hemizygous deletions and uniparental disomy (UPD)
events, accompanying these allelic imbalances.
Genome-wide assessment of CNAs in RCC samples
To have a comprehensive view of all DNA aberrations in
RCC samples, we also assessed CNAs occurring in regions
without significant LOH events (LOH score < 0.15) (Table
3). We found 17 regions with CN gain distributed across
nine chromosomes. These amplifications occurred in at
least 11 samples (41%) and had lengths ranging from 4 to
12 Mb. Chromosome 5 was the most affected, with a 10-
Mb amplification on the p arm and three large regions
covering the entire q arm. In addition, chromosome 7 pre-
sented three amplified regions on both p and q arms,
chromosomes 4 and 11 showed CN gain events spanning
over most of the p arm and part of the q arm, and chro-
mosome 12 had CN gain on most of the q arm. Consider-
ing CN loss events, fewer chromosomes were affected and
for smaller extents but the frequencies of affected samples
were greater (Table 3). We identified six deleted regions,
from 2 to 5 Mb in length, distributed across four chromo-
somes. The most recurrent deletions, observed in 26 sam-
ples (96%), occurred in the region from chr. 3p26.3 to
3p25.1. Moreover, at least 21 samples (78%) had CN loss
on chr. 1p36.32-p36.11, 9q33.3-q34.11 and 22q13.1-
q13.2. Overall, this analysis provided a comprehensive
and detailed view of all CNAs in the 27 RCC samples and,
while confirming a great sample heterogeneity, high-
lighted some recurrent aberrant regions potentially rele-
vant for RCC etiology and worthy of further investigation.
The aberrant genomic regions listed in Tables 2 and 3 con-
tain a total of 493 known genes (Additional file 2). Specif-
ically, 194 genes mapped to CN gain regions distributed
on chr. 4 (3 genes, among which the two protocadherins
PCDH7 and PCDH10), chr. 5 (70 genes, e.g. the cadherin
Table 2: Chromosomal regions affected by significant LOH in the 27 RCC samples.
Chromosome Affected cytobands Region start-end 
positions (Mb)
Total length of LOH 
region (Mb)
No. of samples with 
LOH events (%)
Copy number status
Loss Neutral
(no. of samples)
1 p36.22-36.21 12–13 1 3 (11%) 2 1
2 q36.3 226–227 1 5 (18%) 1 4
3 p26.3 0–1 1 3 (11%) 0 3
p26.2-p25.3 5–9 4 11 (41%) 4 7
p24.3 15–22 4 7 (26%) 0 7
p14.3 56–57 1 8 (30%) 0 8
q22.1 132–133 1 5 (18%) 0 5
6 q16.1 95–96 1 4 (15%) 0 4
q22.1-q22.31 115–119 3 5 (18%) 1 4
q22.31 123–124 1 4 (15%) 3 1
q22.33-q23.2 130–133 3 4 (15%) 1 3
q25.2-q25.3 153–160 2 4 (15%) 3 1
q26 163–164 1 4 (15%) 1 3
9 q31.1-q31.2 107–108 1 4 (15%) 4 0
13 q33.2 104–105 1 3 (11%) 0 3
Regions with LOH score greater than or equal to 0.15 (as calculated by dChip2006) were selected.
Abbreviations: p, short arm; q, long arm; Mb, megabase.Molecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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family genes, the two granzymes GZMK  and  GZMA,
CCNG1 and HMMR), chr. 7 (21 genes, e.g. HGF), chr. 11
(56 genes, among which three caspases and PDGFD), chr.
12 (40 genes), chr. 14 (3 genes) and chr. 19 (1 gene). No
genes were located in amplified regions on chr. 16 and 22.
Similarly, we found 155 genes in CN loss regions distrib-
uted on chr. 1 (47 genes, e.g. IL-22 and IL-28 receptors),
chr. 3 (52 genes, e.g. two IL-17 receptors, VHL  and
TIMP4), chr. 9 (32 genes) and chr. 22 (24 genes). Regard-
ing significant LOH regions, 144 genes were identified,
divided in 105 genes located in regions with concomitant
CN loss and 39 genes in regions with no CN change.
Regarding cellular localization, genes in CN gain regions
preferentially encoded integral plasma membrane pro-
teins, while genes mapping to CN loss regions and LOH
regions encoded proteins located in cytoplasm and intra-
cellular organelle membranes. All these genes may be of
particular interest for RCC pathology, since among them
could be oncogenes or TSGs located in amplified or
deleted regions respectively, and thus potentially involved
in tumor etiology.
Transcriptomic profiling of RCC samples
Comparing 16 tumor to 11 normal cortical samples, we
identified 2922 differentially expressed genes (DEGs),
comprising 1511 up-regulated and 1411 down-regulated
genes (Additional file 3). Functional annotation analysis
revealed that up-regulated genes mostly belonged to the
classes cell cycle (e.g. PCNA, RB1, BRCA1, RGS1, RGS5,
CA9, five cyclins and three caspases), focal adhesion
(including  VEGF,  CAV1,  CAV2,  VIM,  PDGFD, five
integrins, seven collagen genes) and extracellular matrix-
interaction (e.g. CXCR4, four laminins and three cadher-
ins), as well as to Toll-like receptor and T-cell receptor sig-
naling pathways (including TNF and IFN ligands and
receptors, six interleukin receptors, four granzyme genes).
Differently, down-regulated genes were principally related
to aminoacid and fatty acid metabolic pathways (e.g.
AGMAT, four ADH  genes, six ALDH  genes and nine
CYP450 members) and to glycolysis and gluconeogenesis
(e.g.  G6PC,  ALDOB,  FBP1). Considering chromosomal
locations, up-regulated genes were principally located on
chromosomes 5 (138 genes), 11 (106 genes), 12 (102
genes), 7 (90 genes), 4 (75 genes) and 15 (60 genes),
while chromosomes 1 (174 genes), 3 (124 genes), 17 (97
genes), 9 (78 genes) and 14 (56 genes) were enriched in
down-regulated genes.
When our 2922 DEGs were matched to the 294 DEGs that
are commonly detected by the two studies of Jones et al.
and Lenburg et al. [18], similar findings were obtained
regarding 201 genes, comprising 125 up-regulated (e.g.
Table 3: Chromosomal regions affected by DNA copy number alterations.
Chromosome Affected cytobands Region start-end positions (Mb) Total length of aberrant regions (Mb) No. of samples (%)
Regions of CN gain
4 p15.1-q13.1 29–62 5 11 (41%)
q26-q28.3 117–137 5 11 (41%)
5 p15.1-p14.1 17–29 10 11 (41%)
q11.2-q12.3 53–66 5 11 (41%)
q14.3-q21.3 84–105 12 11 (41%)
q23.1-q34 119–163 11 11 (41%)
7 p21.3-p21.2 8–14 5 11 (41%)
q21.11 81–85 4 11 (41%)
q31.31-q31.32 118–122 4 11 (41%)
11 p15.1-q12.1 21–57 11 11 (41%)
q14.2-q22.3 87–107 10 11 (41%)
12 q12-q15 35–69 10 11 (41%)
q21.31-q23.1 82–100 5 11 (41%)
14 q21.1-q21.3 41–48 4 11 (41%)
16 p11.2-q11.1 34–39 5 11 (41%)
19 p12-p11 24–28 4 12 (44%)
22 p13-p11.2 0–9 9 12 (44%)
Regions of CN loss
1 p36.32-p36.31 5–7 2 25 (93%)
p36.11 24–26 2 21 (78%)
3 p26.3-p26.2 3–5 2 26 (96%)
p25.3-p25.1 9–14 5 26 (96%)
9 q33.3-q34.11 128–130 2 21 (78%)
22 q13.1-q13.2 38–40 2 21 (78%)
None of these regions have concomitant significant LOH (score ≥ 0.15).
Abbreviations: CN, copy number; p, short arm; q, long arm; Mb, megabase.Molecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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RGS1,  RGS5,  CXCR4,  LOX,  VEGF,  CAV1,  CAV2,  HIG2,
CA9) and 76 down-regulated genes (e.g., EGF,  CHL1,
DEFB1,  CALB1,  SERPINA5) (Additional file 3). Since
these genes have been found to be differentially expressed
by three separate studies, they are of particular interest,
since among them could be novel markers involved in
RCC oncogenesis.
Integration of copy number data with transcriptomic 
profile
To search for correlations between DNA alterations and
expression profile, the list of genes located in aberrant
regions was matched with DEG list, thus identifying 71
differential genes mapping in aberrant regions (Addi-
tional file 4). Specifically, among the 37 DEGs in CN gain
regions, 27 (73%) were up-regulated in tumor samples
and, of the 27 DEGs in CN loss regions (with and without
concomitant LOH), 14 (52%) were down-regulated.
Moreover, 7 genes mapped to LOH regions with CN neu-
tral status and all had reduced transcriptional levels. These
results illustrate the clear impact of CNAs on gene expres-
sion modulation.
To further investigate the relation between genomic posi-
tion and transcriptional regulation, we assembled a heat
map showing the expression levels of the 71 DEGs plotted
in order of their chromosomal position within aberrant
regions (Figure 2). Interestingly, despite a wide sample
heterogeneity, the groups of tumor and normal samples
were easily distinguishable. Moreover, up-regulated DEGs
were often grouped within amplified regions to form clus-
ters of concordantly modulated genes, as on chr. 5 (12
genes from 5q11.2 to 5q23.3, e.g. ESM1,  GZMK  and
GZMA), chr. 11 (7 genes from 11q11 to 11q22.3, includ-
ing PDGFD and CASP1) and chr. 12 (5 genes from 12q15
to 12q23.1). This distribution highlights the strong rela-
tion between regional DNA amplification and increased
transcriptional level of the corresponding genes. Differ-
ently, in non-gain regions this clusterization of DEGs was
less marked. Exclusively on chr. 3, 11 of the 13 DEGs were
down-regulated and formed a large transcriptionally
reduced region spanning the entire chromosome. Here,
genes in LOH areas with CN neutral were also down-reg-
ulated, supporting the crucial importance in RCC pathol-
ogy of chr. 3 inhibition by various genomic mechanisms.
Altogether, these results demonstrate a striking associa-
tion between DNA alteration profile and gene expression
levels. Moreover, they evidence a stronger influence on
transcriptional modulation by CN gain than CN loss
events. Thus, amplified regions identified in this analysis
are of particular importance since they may contain genes
which, being up-regulated due to underlying DNA ampli-
fication events, could be novel RCC constitutive markers.
Discussion
In this study, we used the 100K SNP mapping array tech-
nology to investigate DNA copy number alterations and
LOH events in a collection of 27 RCC tissue samples.
Simultaneously, transcriptomic analysis was performed to
identify differentially expressed genes potentially
involved in tumor etiology. To narrow down the number
of candidate genes to those whose altered expression level
was attributable to underlying DNA alterations, genomic
and transcriptomic data were combined at genome level.
This permitted us to identify specific chromosomal
regions with concordant alterations in DNA and RNA pro-
files. These regions are of particular interest since they
contain genes which, being transcriptionally modulated
due to genomic alterations, could be novel RCC constitu-
tive markers actively involved in tumor initiation and pro-
gression and useful in clinical applications.
To our knowledge, this is the first study assembling a
genome-wide map of CNAs and LOH events characteriz-
ing RCC pathology. We documented CN loss regions on
chromosomes 3p and 6q, thus confirming the genetic sig-
nature typical of RCC while greatly improving the resolu-
tion compared to previous studies employing cytogenetic
and CGH techniques [2,3,19]. We also observed novel CN
loss regions on chr. 1p, 9q and 22q. We confirmed the
presence of genomic regions affected by LOH on chromo-
somes 3p, 6q and 9q, as previously identified by Thrash-
Bingham et al. in a microsatellite analysis on all chromo-
somes [5]. In addition, our data revealed novel LOH sites
on chromosomes 1p, 2q, 3q and 13q. Taking into account
the DNA copy number status, we distinguished LOH
events associated with CN loss (e.g. on chromosomes 1p
and 9q) highlighting the presence of hemizygous dele-
tions, and LOH events with CN neutral status (e.g. on
chromosomes 2q and 13q) indicating the occurrence of
concomitant genetic mechanisms (including mitotic
recombination, gene conversion or UPD events) to main-
tain the normal diploidy status. It is widely accepted that
regions of LOH accompanied by deletion (representing
the second hit of Knudson's hypothesis) are of particular
interest since they may contain TSGs actively involved in
tumor etiology and thus completely inactivated [10].
Interestingly, we identified a novel LOH and CN loss site
on chromosome 1p36.22-p36.21, a region frequently
deleted also in glioma and neuroblastoma [20] and har-
boring potential TSGs, such as IIp45 (invasion inhibitory
protein 45), found down-regulated in glioblastomas [21],
and  DHRS3, a dehydrogenase/reductase enzyme fre-
quently inactivated by deletion in human neuroblastoma
cell lines [22] and by promoter methylation in melanoma
cell lines [23].
It is known that RCC is characterized by a particular
genetic signature on chr. 3p [24]. We observed deletionsMolecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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TMEV heat map showing differentially expressed genes (DEGs) mapping in aberrant chromosomal regions Figure 2
TMEV heat map showing differentially expressed genes (DEGs) mapping in aberrant chromosomal regions. 
DEGs calculated by SAM analysis and located in regions affected by significant amplification (CN gain regions) or other DNA 
alterations, such as deletion or LOH events (CN non-gain regions) were selected. For each tumor sample (K) and normal con-
trol (C), raw signal intensities converted into expression values by RMA procedure were visualized using a color gradient from 
green to red. For each gene (in row), gene symbol and corresponding cytoband are reported. Abbreviations: p, short arm; q, 
long arm.Molecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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affecting chr. 3p26.3-p26.2 and 3p25.3-p25.1 in 96%
samples, thus confirming the crucial importance of inacti-
vation of these regions in RCC oncogenesis [2]. Moreover,
in 30% of samples we observed LOH with CN neutral sta-
tus on chr. 3p14.3, a region already reported to be fre-
quently affected by LOH in RCC pathology and harboring
the FHIT gene, thought to be involved in tumor suppres-
sion in many neoplasms [25]. Differently, the most fre-
quent LOH area, mapped on chr. 3p26.2-p25.3 and
observed in 41% samples, showed a more complex DNA
arrangement, presenting both CN loss and neutral status
in different tumor samples. This region harbors in 3p25.3
the VHL gene, the main TSG implicated in the early steps
of RCC oncogenesis[4]. As previously reported, in 50–
70% of RCC sporadic forms, VHL gene is completely inac-
tivated through a combination of various mechanisms
such as mutations, promoter methylation, LOH and dele-
tions [4]. VHL protein is a key regulator of the hypoxic
response and controls the transcription of several genes.
Concordantly with a VHL loss of function, we found
increased expression of three known hypoxia-inducible
genes: the carbonic anhydrase CA9, a cell growth regula-
tor; the chemokine receptor CXCR4, which controls met-
astatic spread; and the vascular endothelial growth factor
(VEGF), involved in cell adhesion and angiogenesis.
These genes have already been reported to be up-regulated
in RCC and other human cancers [26].
Combining our transcriptomic data with the publicly
available dataset of Jones et al[18], we found a common
gene signature comprising 201 differential genes. In addi-
tion, we found DEGs already reported as transcriptionally
modulated in RCC samples by previous studies (Table 4).
Although our analysis is limited by its relatively small
sample collection compared to that of Zhao et al. [27], this
is the first study to perform a genome-wide CNAs and
LOH mapping using RCC and matched normal DNA
from the same patients, together with gene profiling anal-
ysis. We documented a strong association between DNA
alterations and gene expression levels and observed that
CN gain events have a stronger influence on transcrip-
tional modulation than CN loss events, in agreement with
previous studies on other tumor types [28]. That gene
amplification greatly enhances expression levels is sup-
ported by ample evidence from mammalian cell lines and
tumors [29]. On the contrary, there are many aneuploidy-
independent mechanisms leading to transcriptional
down-modulation (e.g. mutation, promoter hypermeth-
ylation) [30]. Thus, we suggest that the recently developed
approaches to infer "functional aneuploidy" of tumor
samples by their transcriptomic profile [17,31] should
take into account these differences.
Focusing on regions with concomitant CN gain events
and up-regulated expression levels, we observed that over-
expressed genes often mapped close to one another to
form blocks of concordantly regulated genes. These
regions may contain novel RCC constitutive markers, i.e.
genes with up-regulated expression levels due to DNA
amplification events particular of RCC histotype and nec-
essary for its malignant transformation or progression.
Up-regulated genes whose protein products are released
Table 4: Selection of differentially expressed genes potentially involved in RCC pathology.
Gene symbol (chr) Gene name Biological function Differential expression
in RCC
References
RGS5 (1q) Regulator of G-protein signalling 
5
angiogenesis up [[18,27]]
CXCR4 (2q) Chemokine C-X-C receptor 4 metastatic spread up [[18,26]]
LOX (5q) Lysyl oxidase metastatic spread up [[18,27]]
VEGFA (6p) Vascular endothelial growth 
factor A
angiogenesis up [[18,26]]
CAV1 (7q) Caveolin 1 cell adhesion and extracellular 
matrix interaction
up [[18,41]]
HIG2 (7q) Hypoxia-inducible protein 2 cell growth promotion up [[18,27,42]]
CA9 (9p) Carbonic anhydrase IX cell growth promotion up [[18,43]]
VIM (10p) Vimentin cell adhesion and extracellular 
matrix interaction
up []
NNMT (11q) Nicotinamide N-
methyltransferase
methyltransferase activity up [[18,45]]
EGLN3 (14q) Egl nine homolog 3 cell growth regulation up [[18,27]]
DEFB1 (8p) Defensin beta 1 antimicrobial activity down [[44]]
PVALB (22q) Parvalbumin calcium ion binding down [[44]]
Differentially expressed genes were calculated by SAM analysis comparing 16 RCC tissue samples to 11 normal cortical tissues. Genes were 
selected by comparing our list with the RCC dataset of Jones et al. and with published literature. References specifically reporting a potential role of 
these genes in RCC pathology are indicated.Molecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
Page 9 of 12
(page number not for citation purposes)
to the extracellular space are ideal tumor markers for clin-
ical applications, since they are detectable in patients' bio-
logical fluids without invasive procedures. Interestingly,
within the amplified region on chromosome 5q11-q12,
we found strongly increased expression levels of two adja-
cent genes encoding secreted proteins. ESM1 (endothelial
cell-specific molecule 1, alias endocan), crucially involved
in cell growth regulation, vascular remodeling and angio-
genesis, is dramatically over-expressed in endothelial cells
of kidney cancers and other tumors, in association with
increased tumor aggressiveness and vascularity [32,33].
Moreover, elevated protein levels have been observed in
serum of late-stage lung cancer patients, correlating
inversely with both survival and time to tumor progres-
sion [34,35]. Next, GZMA  gene, encoding a secreted
granzyme involved in cytotoxic T cell-mediated immune
response, is over-expressed in RCC tissues with high con-
tents of natural killer cells and tumor-infiltrating lym-
phocytes [36]. Furthermore, in the amplified region on
chromosome 11q22.3-q23, we found four adjacent over-
expressed genes, including PDGFD, which encodes a
secreted activator of the inflammatory response playing
an important role in angiogenesis and is over-expressed in
prostate carcinoma [37] and many tumor, including RCC,
cell lines [38], and CASP1, which is up-regulated in pan-
creatic adenocarcinomas [39] and presents increased
plasma levels in metastatic melanoma patients [40]. These
genes and their encoded proteins will be further studied to
determine if they have roles in RCC pathology and if they
could be novel RCC biomarkers detectable in clinical bio-
logical fluids.
Conclusion
By combining genomic and transcriptomic profiles from
a collection of RCC samples, we identified at high resolu-
tion specific genomic regions concomitantly affected by
DNA alterations and modulated expression levels. This
study lays the groundwork for a more detailed search for
novel RCC biomarkers associated with these aberrant
regions, in particular in areas with increased DNA copy
number. The integration of data from both DNA and RNA
profiles should greatly improve the specificity of analysis
and increase the possibility of identifying the genetic
causes of tumor pathologies. Moreover, data from the fol-
low-up evaluations of these RCC patients should enable
us to validate this novel genomic RCC fingerprint.
Methods
Collection of RCC tissue samples and DNA/RNA 
extraction
A total of 30 patients with a diagnosis of clear cell renal
carcinoma (RCC) were scheduled for surgical removal of
kidney at San Paolo Hospital (University of Milan, Italy).
All patients provided informed consent for the use of kid-
ney tissues and blood samples in this multi-center
research project, which was carried out according to the
Declaration of Helsinki (as revised in 2004) and was
approved by the ethic committee of San Paolo Hospital.
Prior to surgery, a whole blood sample was collected from
each case and stored at -20°C. Immediately after surgical
removal of the kidney, a pathologist excised bioptic sam-
ples from both the tumor and the normal cortical areas.
Fresh tissue samples were immersed in RNA later solution
(Qiagen, Hilden, Germany) and stored at -80°C. Tumor
masses were measured for longest diameter and scored for
stage and nuclear grade according to the UICC pTNM stag-
ing system and Fuhrman's grading system, respectively.
Genomic DNA was extracted from tumor and blood sam-
ples using standard proteinase K-cell lysis and phenol/
chloroform procedures. DNA was quantified by ND-1000
spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE) and stored at 4°C. Total RNA was extracted from
tumor and cortical samples using RNeasy Mini extraction
kit (Qiagen). Samples were quantified by spectrophotom-
etry and assessed for quality by microcapillary electro-
phoresis on 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). Total RNA was considered suitable for micro-
array analysis if the 28S/18S rRNA ratio was greater than
1.3. RNA samples were stored at -80°C until use. Overall,
we obtained good-quality DNA from 27 tumor tissues
and matched blood samples, and good-quality RNA from
16 tumor tissues and 11 healthy cortical samples (listed in
Additional file 5).
Sample preparation for Affymetrix GeneChip® analysis
Genomic DNA from the 27 tumor tissues and correspond-
ing blood samples was prepared for whole-genome SNP
mapping using both GeneChip® Human Mapping 50K
Xba and 50K Hind assay kits (Affymetrix, Santa Clara,
CA), according to the manufacturer's protocols. The com-
bination of the two GeneChip® Human Mapping arrays,
referred to as 100K SNP mapping array set, allowed the
genotyping of 116204 SNPs distributed over all chromo-
somes, excluding the Y chromosome. Total RNA from 16
tumor and 11 cortical tissues was prepared using Gene-
Chip® Two-Cycle Target Labeling assay kit (Affymetrix),
according to the manufacturer's protocols, and hybridized
onto GeneChip® HG-U133 Plus 2.0 arrays (for complete
information about methods see Additional file 6). All
GeneChip® data files are available at ArrayExpress reposi-
tory (E-TABM-282, E-TABM-283 and E-TABM-284).
Assessment of genomic CNAs and LOH events in RCC 
samples
Genomic regions with CNAs were first assessed using
Copy Number Analyzer for GeneChip software (CNAG,
v2.0). We compared the 27 tumor samples to the corre-
sponding blood samples and displayed in a unique plot
all CNAs occurring along each chromosome (for furtherMolecular Cancer 2008, 7:6 http://www.molecular-cancer.com/content/7/1/6
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information see Additional file 6). Datasets from only
GeneChip® 50K Hind arrays were used. CNAs were also
assessed using dChip2006 software, which offers the pos-
sibility of combining the two datasets from GeneChip®
50K Xba and 50K Hind arrays. dChip2006 was used to
calculate a raw CN value for each SNP in tumor and nor-
mal samples. Then, we implemented a home-made proce-
dure to calculate aberrant regions (for complete
description of the procedure see Additional file 6). More-
over, dChip2006 was used to identify LOH events and to
define a summary LOH score for each SNP taking into
account all the 27 sample pairs. Then, applying a home-
made procedure, we calculated regions affected by statisti-
cally significant LOH (for details see Additional file 6). In
addition, the CN status of these regions was evaluated to
distinguish LOH events with and without CN
changes.Using the UCSC database, all genes located in
aberrant regions were identified. Literature mining was
carried out with MILANO tool, using specific cancer-
related keywords.
Transcriptomic profiling and integration with copy number 
data
Differential expression profiling was performed by SAM
analysis comparing the 16 tumor to the 11 normal cortical
samples to identify differentially expressed genes (DEGs).
Functional annotation of the DEG list was carried out
using DAVID database (for details about procedures see
Additional file 6). Furthermore, we compared our DEG
list with the RCC microarray expression dataset published
by Jones et al. and including differential genes that overlap
with the dataset provided by Lenburg et al. [18]. The DEGs
found in common were functionally annotated with
DAVID.
Finally, the list of genes in chromosomal regions with sig-
nificant CNAs was compared to our DEG list to investigate
the expression levels of genes in aberrant regions. For all
genes found in common, expression values calculated for
each tumor and normal sample were plotted in a heat
map using the TIGR Multiple Experiment Viewer (TMEV,
v4.0) (for details, Additional file 6).
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Additional file 1
Chromosomal maps of LOH regions and DNA copy number altera-
tions in the 27 RCC samples. Each map represents one single chromo-
some (from 1 to 22). For each tumor sample compared to corresponding 
normal control, probability of LOH events as calculated by dChip2006 
was displayed along the entire chromosome, from p to q arm, according to 
the following color-coded legend: blue, 1; yellow, 0.5; white, 0. Similarly, 
inferred copy number values calculated by dChip2006 were plotted using 
a color scale (from white to red) to indicate increasing copy number value. 
Abbreviations: p, short arm; q, long arm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-6-S1.pdf]
Additional file 2
Genes mapping in regions harbouring recurrent DNA copy number 
alterations or significant LOH events. Genes are listed in order of chro-
mosome and genomic start position. Using UCSC genome browser a com-
plete gene annotation was retrieved including Entrez Gene ID, Gene 
symbol, Gene name, chromosome, cytoband and genomic start and end 
positions. In addition, each gene is flagged by a label (CN gain, CN loss, 
LOH+CN loss, LOH+CN neutral) indicating the type of DNA alteration 
occurring in the corresponding region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-6-S2.xls]
Additional file 3
Complete list of differentially expressed genes (DEGs) in RCC tissues 
as compared to normal cortical samples. GeneChip® HG-U133 Plus 2.0 
array probesets were annotated using an updated custom chip description 
file and metaprobes corresponding to unique Entrez Gene IDs having dif-
ferential expression levels in tumor samples as compared to normal sam-
ples were calculated by the t statistic of the significance analysis of 
microarrays (SAM). For each listed gene, corresponding t score and fold 
change calculated by SAM analysis are reported, in addition to a flag (up/
down) indicating the expression level in our RCC sample set. Further-
more, the last two columns indicate DEGs and corresponding fold change 
(FC) found in common between the two studies of Jones et al. and Len-
burg et al.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
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